Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain

Potential best-in-class non-opioid Na v 1.8 inhibitor, LTG-305 aims to provide safer treatment for chronic pain by targeting underlying mechanisms of pain at its source Trial will evaluate safety, tolerability, and pharmacokinetics of LTG-305 in healthy volunteers through single- and